25May 2023
Etrasimod for ulcerative colitis: evaluating phase III results

Etrasimod for ulcerative colitis: evaluating phase III results

Etrasimod, a sphingosine-1-phosphate receptor modulator, has shown positive results in clinical trials for moderately-to-severely active ulcerative colitis. It is an oral treatment option that has demonstrated efficacy and safety. However, more data on its long-term effectiveness and safety are still needed. Overall, etrasimod presents promise as a potential new therapy for patients with ulcerative colitis.

  • #gastroenterology

Like

Save

Share